<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668616</url>
  </required_header>
  <id_info>
    <org_study_id>170200</org_study_id>
    <nct_id>NCT00668616</nct_id>
  </id_info>
  <brief_title>Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes</brief_title>
  <official_title>Cyclophosphamid + Farmorubicin® With Subsequent Administration of Taxol® (q3w) Versus Intensified Administration of Farmorubicin® Followed by Taxol® (q2w) in the Adjuvant Treatment of Breast Cancer in Patients With 1-3 Afflicted Lymph Nodes (1-3 LK+)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Eastern Germany Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Eastern Germany Society of Gynaecologic Oncology</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a treatment with 4 cycles anthracycline +
      cyclophoshamide followed by administration of 4 cycles paclitaxel is more effective than
      therapy with 4 cy&lt;cles of anthracycline adminbistration followed by 4 cycles of paclitaxel
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free time</measure>
    <time_frame>every 3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1034</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Epirubicin, Paclitaxel</intervention_name>
    <description>4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin, Paclitaxel, Filgrastim</intervention_name>
    <description>cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with histologically proven breast cancer (pT1/pT2/pT3, pN1, N0)

          -  ECOG performance status 0-1

          -  start of adjuvant therapy not later than 4 weeks after surgery

          -  hematology: platelets at least 100xGpt/l, neutrophiles at least 2xGpt/l

          -  normal liver function as defined by: bilirubine till 1.5 x normal value, SGOT/SGPT
             till 1.25 x normal value

          -  normal kidney function as defined by: creatine till 1.5 x normal value

          -  negative pregnancy test for patients before menopause and effective contraception

          -  written informed consent

        Exclusion Criteria:

          -  prior radiation, chemotherapy, hormontherapy and immunotherapy

          -  patients with more than 3 afflicted lymph nodes

          -  afflicted lymph nodes on the cantralateal side and/or afflicted supraclavicular or
             intraclavicular lymph nodes

          -  bilateral breast cancer or second carcinoma of the breast

          -  inflammatory breast cancer and/or distant metastases

          -  existing clinically relevant peripheral neuropathie

          -  heart infection during the last 6 months or therapeutically not compensated heart
             failure or cardiac arrhythmias of at least LOWN II

          -  patients with active infections and/or not controlled hypercalcemia

          -  pregnant or breastfeeding women or women of child-bearing age who do not use effictive
             contrazeptiva
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oskar-Ziethen-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>July 28, 2010</last_update_submitted>
  <last_update_submitted_qc>July 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2010</last_update_posted>
  <keyword>breast cancer with 1-3 afflicted axillary lymph nodes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

